loading page

Opioid Response in an Individual with Altered CYP2D6 Activity: Implications of a Pharmacogenomics Case
  • +3
  • Tyler Ballinghoff,
  • Kevin Bain,
  • Adriana Matos,
  • Chandni Bardolia,
  • Jacques Turgeon,
  • Nishita Amin
Tyler Ballinghoff
Tabula Rasa HealthCare
Author Profile
Kevin Bain
Tabula Rasa HealthCare
Author Profile
Adriana Matos
Tabula Rasa HealthCare
Author Profile
Chandni Bardolia
Tabula Rasa HealthCare
Author Profile
Jacques Turgeon
Tabula Rasa HealthCare
Author Profile
Nishita Amin
Tabula Rasa HealthCare
Author Profile

Abstract

The benefits of opioid use in older adults to manage chronic non-cancer pain must outweigh the risks as these individuals are more susceptible to the side effects and drug interactions associated with opioids. Pharmacogenomic testing supports clinicians to select an appropriate opioid therapy while minimizing these risks.